Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Running, not enrolling · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 1

In brief

The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.

Key facts

Study ID
NCT04598893
Run by
Provention Bio, a Sanofi Company
People needed
188
Starts
2020-10-26
Expected to finish
2026-11-01
Last updated by the study team
2025-12-09

Who can join

Age: 9 and older, up to 19. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.